{"id":"NCT03031782","sponsor":"Novartis Pharmaceuticals","briefTitle":"Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)","officialTitle":"A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-23","primaryCompletion":"2020-10-07","completion":"2020-11-09","firstPosted":"2017-01-26","resultsPosted":"2022-08-15","lastUpdate":"2022-08-15"},"enrollment":86,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Juvenile Psoriatic Arthritis","Enthesitis-related Arthritis"],"interventions":[{"type":"DRUG","name":"secukinumab","otherNames":["AIN457"]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"Treatment Period 2 - active","type":"EXPERIMENTAL"},{"label":"Treatment Period 2 - placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA). The study was divided into 3 parts (plus a post-treatment follow-up period) consisting of open-label, single-arm active treatment in Treatment Periods 1 and 3 and a randomized, double-blind, placebo controlled, event-driven withdrawal design in Treatment Period 2","primaryOutcome":{"measure":"Number of Participants Experiencing a Flare During Treatment Period 2","timeFrame":"From Week 12 until max Week 104","effectByArm":[{"arm":"AIN457 in Treatment Period 2","deltaMin":10,"sd":null},{"arm":"Placebo in TP2","deltaMin":21,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["United States","Belgium","Germany","Italy","Poland","Russia","South Africa","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35961761"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":48},"commonTop":["Nasopharyngitis","Nausea","Upper respiratory tract infection","Diarrhoea","Cough"]}}